drug · small molecule
levodopa
Marketedupdated 6mo agoby PureIMS BV🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 8- drugINBRIJA31 co-mentions · 8 sources
- tagApproval22 co-mentions · 6 sources
- druglevodopa CR21 co-mentions · 8 sources
- drugSINEMET CR12 co-mentions · 3 sources
- drugentacapone10 co-mentions · 2 sources
- tagRecall3 co-mentions · 1 sources
- companyRising Pharma Holdings Inc3 co-mentions · 1 sources
- drug(carbidopa + levodopa)1 co-mentions · 1 sources
Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for parkinson disease and injury and 22 investigational indications.
indications
investigational
Parkinson's Disease
targets
D(3) dopamine receptor
all catalysts(5)
approval · 5
Dec 21, 2018
approval
INBRIJA (LEVODOPA) — FDA approval
levodopa
→
Aug 29, 2019
approval
INBRIJA (LEVODOPA) — FDA approval
levodopa
→
Aug 31, 2020
approval
INBRIJA (LEVODOPA) — FDA approval
levodopa
→
Aug 31, 2020
approval
INBRIJA (LEVODOPA) — FDA approval
levodopa
→
Mar 31, 2026
approval
INBRIJA (LEVODOPA) — FDA approval
levodopa
→
Trials studying levodopa
- phase2A Study of the Efficacy and Safety of Carbidopa-Levodopa Extended-Release Tablets in Patients With Parkinson's Disease
- —Real-world Patient Experiences With Inbrija®
- phase3A Study to Evaluate the Efficacy and Safety of HRG2010 in Parkinson's Disease With Motor Fluctuations
- phase1A Study to Assess Effect of Dosing Intervals on Multiple-Dose Pharmacokinetics of WD-1603 Taken Before Meals in Healthy Participants
- phase1A Pilot Comparative Bioavailability Study of Levodopa Administered Via Levodopa Cyclops® Relative to INBRIJA®
- —Observational Small Intestine and Blood Fingerprint (SmIle) Study in Parkinson's Disease
- phase2Pharmacokinetics,Pharmacodynamics,Efficacy and Safety of HRG2010 in Parkinson's Disease Patients With Motor Fluctuations
- phase1A Safety, Tolerability, and Plasma Concentration Study of Levodopa/Carbidopa Subcutaneous Solution (ND0612) in Parkinson's Disease (PD) Patients
Patent cliff
source: FDA Orange Bookfirst barrier falls
Feb 3, 2029
~2.2 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (6)
- Oct 21, 2033method-of-use (U-2484)US 12458615
- Nov 16, 2032formulationUS 8545878
- Nov 16, 2032formulationUS 8685442
- Nov 16, 2032formulationUS 8945612
- Nov 16, 2032formulationUS 9393210
- Feb 3, 2029method-of-use (U-2484)US RE437112.2y
News(9)
- Aspen raises a $141M IPO in pursuit of a cell therapy for Parkinson’sThe San Diego biotechnology startup is one of several firms working on a cutting-edge technique with the potential to slow or even halt the neurodegenerative condition.biopharma_dive · 16d ago
- Parkinson’s-focused Aspen and bispecific biotech Bambusa plan IPOsParkinson’s disease cell therapy-focused Aspen Neuroscience and bispecific biotech Bambusa Therapeutics are the latest drug developers to eye up a public listing.fiercebiotech · 1mo ago
- Cerevance Parkinson’s drug shortens 'off time' in Ph. 3, paving path to FDAThe Takeda spinout showed that a high dose of solengepras can shorten the periods during which difficult Parkinson’s disease symptoms like involuntary movements and sleepiness.biospace · 1mo ago
- A Takeda spinout builds case for its Parkinson’s drugCerevance plans to meet with the FDA to determine next steps for a new kind of medicine known as solengepras, now that it has Phase 3 data in hand.biopharma_dive · 1mo ago
- Cerevance rescues its Parkinson's drug with phase 3 winCerevance's oral non-dopaminergic therapy has redeemed itself by improving both motor and non-motor symptoms in a phase 3 Parkinson's disease study.fiercebiotech · 1mo ago
- AbbVie wins FDA approval for Parkinson’s drug from $8.7B Cerevel takeoverIn the Phase 3 TEMPO program, AbbVie’s Juvmo elicited significant improvements in motor symptoms and prolonged periods with good symptom control.biospace · 1mo ago
- Reeling from past failures, Parkinson's pipeline enters 'era of diversification'While some drugmakers continue to walk the alpha-synuclein antibody path, others like AC Immune opt for new approaches that could bring the first-ever disease-modifying therapy for Parkinson's dise…biospace · 2mo ago
- BioVie shares halve on murky Parkinson’s disease readoutBioVie’s stock fell by nearly 50% as the biotech claimed victory in a mid-stage Parkinson’s disease trial using an alternative endpoint to the primary clinical goal.biospace · 3mo ago
- AbbVie shares pressured as Q2 I&I beat falls below investor expectationsAbbVie investors’ sky-high expectations led to a 4% share decline on Friday as the company reported more modest consensus beats than expected.biospace · 3mo ago
Data sources
last refreshed 5h ago
Found something off?
comments(0)
5-min edit window · permanent after that